News
VANI
1.250
0.00%
0.000
Weekly Report: what happened at VANI last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at VANI last week (0708-0712)?
Weekly Report · 07/15 11:19
VIVANI MEDICAL SHARES UP 5.6% ON PLANS TO BEGIN HUMAN TRIAL FOR OBESITY IMPLANT
Reuters · 07/11 13:34
BUZZ-Vivani Medical up on plans to begin first human study for obesity implant
Shares of Vivani Medical rise 8.6% to $1.35 premarket. Company expects to begin first human study for obesity implant in Q4 in Australia. Study will test its experimental GLP-1 implant for chronic weight management in obese patients. Data from the trial is projected to be available in 2025.
Reuters · 07/11 12:46
VIVANI MEDICAL INC: EXPECTS TO INITIATE FIRST CLINICAL STUDY SUPPORTING NPM-115 PROGRAM IN Q4
Reuters · 07/11 12:00
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Vivani Medical Inc. Expects to initiate the first clinical study for the NPM-115 program in Australia in the fourth quarter of 2024. The study will evaluate the GLP-1 implant for chronic weight management in patients who are obese or overweight.
Benzinga · 07/11 11:29
Weekly Report: what happened at VANI last week (0701-0705)?
Weekly Report · 07/08 11:21
Weekly Report: what happened at VANI last week (0624-0628)?
Weekly Report · 07/01 11:21
Weekly Report: what happened at VANI last week (0617-0621)?
Weekly Report · 06/24 11:29
Weekly Report: what happened at VANI last week (0610-0614)?
Weekly Report · 06/17 11:20
Analysts Are Bullish on Top Healthcare Stocks: Vivani Medical (VANI), Shattuck Labs (STTK)
TipRanks · 06/14 15:31
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Signet Jewelers Limited shares dipped 12.5% to $94.81 on Thursday. The company reported mixed first-quarter earnings. Elon Musk's Tesla Inc. Shares rose 6% after posting better-than-expected quarterly results on Wednesday. Gainers BioRestorative Therapies, Inc. And Barnes & Noble Education also rose in the mid-day.
Benzinga · 06/13 18:07
BUZZ-U.S. STOCKS ON THE MOVE-ACI Worldwide, enCore Energy, Adobe
S&P 500 and Dow indexes slip as investors weigh hawkish Fed projections against data signaling cooling inflation. Strength in chip stocks supported the Nasdaq. The Dow Jones Industrial Average was down 0.35% at 38,576.01. The top three Nasdaq percentage gainers were Broadcom and Barnes & Noble.
Reuters · 06/13 17:51
BUZZ-U.S. STOCKS ON THE MOVE-Williams-Sonoma, ACI Worldwide, enCore Energy
S&P 500 and Nasdaq indexes hit record highs on Thursday. Chip stocks jump after lower-than-forecast producer inflation data fanned expectations of interest-rate cuts from the Fed. Dow Jones Industrial Average down 0.51% to 38,513.74; Nasdaq up 0.23%.
Reuters · 06/13 16:08
Why GLP-1 Developer Vivani Medical's Stock Is Climbing
Vivani Medical, Inc. Shares are trading higher after the company announced the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119. Vivani shares are moving on heavy trading volume following the company's announcement. More than 11.7 million shares have already been traded in the session. The company is developing a miniature implant for type 2 diabetes.
Benzinga · 06/13 15:18
Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial
Dow Jones · 06/13 15:13
VIVANI MEDICAL SHARES UP 14% AS US FDA LIFTS CLINICAL HOLD ON TRIAL FOR DIABETES TREATMENT IMPLANT
Reuters · 06/13 13:32
BUZZ-U.S. STOCKS ON THE MOVE-Vivani, Vanda, Sarepta
Futures tracking the Nasdaq leapt on Thursday on gains in heavyweight technology stocks. The Federal Reserve is expected to ease interest rates in September despite projecting just one cut this year. The top two NYSE percentage gainers premarket were John Wiley and Vanda Pharmaceuticals. Virgin Galactic was the top Nasdaq percentage loser.
Reuters · 06/13 13:29
Vivani Medical gains as FDA lifts clinical hold on GLP-1 implant
Vivani Medical gains as FDA lifts clinical hold on GLP-1 implant. Shares of Vivani Medical added ~10% premarket Thursday. The U.S. FDA lifted the clinical hold on NPM-119, a medical implant designed to deliver GLp-1 receptor agonist.
Seeking Alpha · 06/13 12:58
BUZZ-Vivani jumps as US FDA lifts clinical hold on trial for diabetes treatment implant
Reuters · 06/13 12:45
More
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Company’s lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Company’s implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.